PBI 200
Alternative Names: PBI-200Latest Information Update: 17 Jun 2024
At a glance
- Originator Pyramid Biosciences
- Class Antineoplastics
- Mechanism of Action TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 12 Nov 2022 Pyramid Biosciences completes phase-I pharmacokinetics trial (In volunteers) in USA (PO, Tablet) (NCT05692570)
- 09 Sep 2022 Pyramid Biosciences initiates a phase-I pharmacokinetics trial (In volunteers) in USA (PO, Tablet) (NCT05692570)
- 06 Jul 2022 PBI 200 receives Orphan Drug status for Solid tumours (Metastatic disease, Late-stage disease) in USA